Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
The Journal of Clinical Psychiatry|April 11, 2009
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidoneJohn W Newcomer, Robert E Ratner, Jan W Eriksson, et al.
Community Mental Health Journal|March 27, 2012
Implementation of a weight loss program for Latino outpatients with severe mental illnessChristina Mangurian, Simriti Chaudhry, Lucia Capitelli, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 22, 2007
Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patientsDan W Haupt, Peter A Fahnestock, Karen A Flavin, et al.
Scandinavian Journal of Child and Adolescent Psychiatry and Psychology|June 28, 2016
Behavioral Weight Loss Treatment in Antipsychotic Treated YouthGinger E Nicol, Rachel P Kolko, Monica Mills, et al.
CNS Spectrums|December 31, 2005
From clinical research to clinical practice: a 4-year review of ziprasidoneCharles B Nemeroff, Jeffrey A Lieberman, Peter J Weiden, et al.
Psychiatric Services (Washington, D.C.)|September 2, 2017
Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving AntipsychoticsAndrew W Mulcahy, Sharon-Lise Normand, John W Newcomer, et al.
The American Journal of Psychiatry|August 15, 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 StudyChristoph U Correll, John W Newcomer, Bernard Silverman, et al.
BMC Psychiatry|November 8, 2022
CRANIUM: a quasi-experimental study to improve metabolic screening and HIV testing in community mental health clinics compared to usual careAlison R Hwong, D Nyasha Chagwedera, Marilyn Thomas, et al.
Journal of Clinical Psychopharmacology|June 24, 2010
A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trialStephen M Stahl, Ashok Malla, John W Newcomer, et al.
The Journal of Clinical Psychiatry|September 22, 2021
PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia PatientsAnne Le Moigne, John Csernansky, Robert A Leadbetter, et al.
Pageof 10